MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E

Xiang Tan,Zuotao Wu,Mingwu Chen

DOI: https://doi.org/10.2147/ott.s454902

IF: 4

2024-04-09

OncoTargets and Therapy

Abstract:Xiang Tan, &ast Zuotao Wu, &ast Mingwu Chen Department of Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Mingwu Chen, Department of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, People's Republic of China, Email Previous case reports have demonstrated the effectiveness of combination therapy involving EGFR TKI, BRAF inhibitor dabrafenib, and MEK inhibitor trametinib in metastatic non-small-cell lung cancer (NSCLC) patients with acquired BRAF V600E and EGFR mutations. However, the current literature does not provide any reports on the presence of resistant mutations in response to the administration of three-drug combination therapy. Exploring the resistance mechanism of targeted therapy is helpful to optimize the subsequent treatment strategy of patients. Herein, we report a case of a patient with advanced EGFR positive lung adenocarcinoma harboring an acquired BRAF V600E mutation who responded to the combination of furmonertinib, dabrafenib, and trametinib therapy. Unexpectedly, a MAP2K1 K57N acquired mutation was identified by NGS (Next-generation sequencing) analysis of re-biopsy tumor tissue after the patient was resistant to three-drug therapy. As far as we know, this is the first report demonstrating that the efficacy of using combination of furmonertinib and BRAF / MEK inhibitors and the MAP2K1 K57N mutation serves as a resistant mechanism to the three-drug therapy. This novel finding not only revealed a new resistant mutation but also had important implications for the identification of effective patients to EGFR/BRAF/MEK combination therapy. Keywords: MAP2K1, furmonertinib, lung adenocarcinoma, EGFR, mutation Approximately 40–60% of Chinese patient with NSCLC harbor EGFR somatic mutations who can benefit from EGFR TKIs therapy. Unfortunately, most patients who initially respond to TKIs eventually develop acquired resistance within 1–2 years of treatment. 1 Clarifying the potential drug resistance mechanism provides an important theoretical basis for overcoming the resistance of TKIs. BRAF V600E has been recognized as a causal factor for osimertinib resistance in 3% of lung cancer cases, both in first- and second-line therapy. 2 The Food and Drug Administration (FDA) approved the combination of dabrafenib and trametinib for the treatment of people with nearly any type of advanced solid tumor that has BRAF V600E. The BRAF protein signals can be effectively inhibited by dabrafenib, while the MEK protein signals can be inhibited by trametinib. Several case reports have demonstrated that NSCLC patients harboring EGFR TKIs sensitive mutation and acquired BRAF V600E can benefit from osimertinib in combination with dabrafenib and trametinib. 3–5 These findings have made us curious to probe whether a novel third-generation EGFR tyrosine-kinase inhibitor furmonertinib combined with BRAF - and MEK - inhibitors are effective against advanced NSCLC harboring EGFR mutation and the acquired resistance mutation BRAF V600E. A 71-year-old Chinese female was diagnosed with stage IV adenocarcinoma of the right lung in July 2020 (Figure 1A). NGS analysis of tumor tissue revealed the presence of an EGFR exon 19 deletion ( EGFR E746_A750del) mutation. Icotinib is a highly selective first-generation EGFR TKI which is approved by National Medical Products Administration (NMPA) for use in China as first-line monotherapy in patients with NSCLC with somatic EGFR mutations. 6 The patient received three cycles of icotinib treatment, and reexamination via computed tomography (CT) indicated clinical benefit (Figure 1B). However, approximately 12 months later, follow-up CT imaging revealed slow progressive disease (PD) and the patient experienced severe adverse effects, such as diarrhea and rash. Therefore, the patient received rebiopsy and the EGFR T790M mutation was identified. The administration of osimertinib was initiated for the patient in June 2021 and demonstrated favorable tolerability (Figure 1C). However, a CT scan after one year of treatment revealed the presence of progressive lesions in the right lung (Figure 1D). Subsequent NGS analysis (YuceOne ® Pro+, Yucebio Ltd., Shenzhen, China) of soft tissue metastasis identified EGFR E746_A750del, EGFR T790M, TP53 R156Afs*14 and acquired BRAF V600E mutations (Figure 2B). Consequently, in August 2022, the patient underwent a combination therapy co -Abstract Truncated-

oncology,biotechnology & applied microbiology